Abstract
Purpose
We aimed to investigate the effects of FSH for promoting spermatogenesis in mice with low-dose doxorubicin-induced spermatogenesis impairment.
Methods
Eight-wk-old male imprinting control region mice were divided into three groups. Groups D and F received 0.5 mg/kg of doxorubicin twice weekly for 5 weeks. Group C received saline instead of doxorubicin. After inducing spermatogenesis impairment, group D was treated daily with saline for 4 weeks. Group F was given 1 IU of recombinant human FSH daily for 4 weeks. Spermatogenesis recovery was evaluated based on the testis weight, sperm count, histological assessment, and mating. The percentage of sperm with unfragmented deoxyribonucleic acid (DNA) was analyzed by single-cell pulsed-field gel electrophoresis, and the serum FSH levels were measured.
Results
The elevation of serum FSH advanced slowly. The testis weight, sperm count, percentage of seminiferous tubules with spermatogenesis, percentage of sperm with unfragmented DNA and pregnancy rate were significantly increased by the administration of FSH.
Conclusion
Our study findings indicated that the immediate administration of exogenous FSH can promote the recovery from impaired spermatogenesis induced by low-dose doxorubicin before endogenous FSH increases to the maximum level.
Similar content being viewed by others
References
Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancer. J Clin Oncol. 1997;15:239–45.
Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12–7.
Hsiao W, Stahl PJ, Osterberg EC, Nejat E, Palermo GD, Rosenwaks Z, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol. 2011;29:1607–11.
Chung K, Irani J, Efymow B, Blasco L, Patrizio P. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol. 2004;113 Suppl 1:S7–11.
Meistrich ML, Kangasniemi M. Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. J Androl. 1997;18:80–7.
Udagawa K, Ogawa T, Watanabe T, Tamura Y, Kita K, Kubota Y. Testosterone administration promotes regeneration of chemically impaired spermatogenesis in rats. Int J Urol. 2006;13:1103–8.
Aminsharifi A, Shakeri S, Ariafar A, Moeinjahromi B, Kumar PV, Karbalaeedoost S. Preventive role of exogenous testosterone on cisplatin-induced gonadal toxicity: an experimental placebo-controlled prospective trial. Fertil Steril. 2010;93:1388–93.
Ruwanpura SM, McLachlan RI, Stanton PG, Meachem SJ. Follicle-stimulating hormone affects spermatogonial survival by regulating the intrinsic apoptotic pathway in adult rats. Biol Reprod. 2008;78:705–13.
Ruwanpura SM, McLachlan RI, Meachem SJ. Hormonal regulation of male germ cell development. J Endocrinol. 2010;205:117–31.
Gnanaprakasam MS, Chen CJ, Sutherland JG, Bhalla VK. Receptor depletion and replenishment processes: in vivo regulation of gonadotropin receptors by luteinizing hormone, follicle stimulating hormone and ethanol in rat testis. Biol Reprod. 1979;20:991–1000.
Trivedi PP, Tripathi DN, Jena GB. Hesperetin protects testicular toxicity of doxorubicin in rat: role of NFkappaB, p38 and caspase-3. Food Chem Toxicol. 2011;49:838–47.
Sudo K. An experimental model of Adriamycin-induced spermatogenic disorder in mice (1): histological and functional analysis. J Med Soc Toho. 1991;38:462–75.
Singh J, Handelsman DJ. The effects of recombinant FSH on testosterone-induced spermatogenesis in gonadotrophin-deficient (hpg) mice. J Androl. 1996;17:382–93.
Eddy EM. Male germ cell gene expression. Recent Prog Horm Res. 2002;57:103–28.
Sato K, Sueoka K, Tanigaki R, Tajima H, Nakabayashi A, Yoshimura Y, et al. Green tea extracts attenuate doxorubicin-induced spermatogenic disorders in conjunction with higher telomerase activity in mice. J Assist Reprod Genet. 2010;27:501–8.
Kanatsu-Shinohara M, Toyokuni S, Morimoto T, Matsui S, Honjo T, Shinohara T. Functional assessment of self-renewal activity of male germline stem cells following cytotoxic damage and serial transplantation. Biol Reprod. 2003;68:1801–7.
Zohni K, Zhang X, Tan SL, Chan P, Nagano MC. The efficiency of male fertility restoration is dependent on the recovery kinetics of spermatogonial stem cells after cytotoxic treatment with busulfan in mice. Hum Reprod. 2012;27:44–53.
Kaneko S, Yoshida J, Ishikawa H, Takamatsu K. Single-cell pulsed-field gel electrophoresis to detect the early stage of DNA fragmentation in human sperm nuclei. PLoS One. 2012;7, e42257.
Meistrich ML, Shetty G. Inhibition of spermatogonial differentiation by testosterone. J Androl. 2003;24:135–48.
Foresta C, Bettella A, Spolaore D, Merico M, Rossato M, Ferlin A. Suppression of the high endogenous levels of plasma FSH in infertile men are associated with improved Sertoli cell function as reflected by elevated levels of plasma inhibin B. Hum Reprod. 2004;19:1431–7.
Lu CC, Meistrich ML. Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Res. 1979;39:3575–82.
Imahie H, Adachi T, Nakagawa Y, Nagasaki T, Yamamura T, Hori M. Effects of Adriamycin, an anticancer drug showing testicular toxicity, on fertility in male rats. J Toxicol Sci. 1985;20:183–93.
Meistrich ML, Goldstein LS, Wyrobek AJ. Long-term infertility and dominant lethal mutations in male mice treated with adriamycin. Mutat Res. 1985;152:53–65.
Lui RC, Laregina MC, Herbold DR, Johnson RF. Testicular cytotoxicity of intravenous doxorubicin in rats. J Urol. 1986;136:940–3.
Meistrich ML, Wilson G, Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res. 1999;59:3557–60.
Xin YF, You ZQ, Gao HY, Zhou GL, Chen YX, Yu J, et al. Protective effect of Lycium barbarum polysaccharides against doxorubicin-induced testicular toxicity in rats. Phytother Res. 2012;26:716–21.
Meachem SJ, Wreford NG, Stanton PG, Robertson DM, McLachlan RI. Follicle-stimulating hormone is required for the initial phase of spermatogenic restoration in adult rats following gonadotropin suppression. J Androl. 1988;19:725–35.
Sinha-Hikim AP, Swerdloff RS. Temporal and stage-specific effects of recombinant human follicle-stimulating hormone on the maintenance of spermatogenesis in gonadotrophin-releasing hormone antagonist-treated rat. Endocrinology. 1995;136:253–61.
McLachlan RI, Wreford NG, de Kretser DM, Robertson DM. The effects of recombinant follicle-stimulating hormone on the restoration of spermatogenesis in the gonadotropin-releasing hormone-immunized adult rat. Endocrinology. 1995;136:4035–43.
Haywood M, Spaliviero J, Jimemez M, King NJ, Handelsman DJ, Allan CM. Sertoli and germ cell development in hypogonadal (hpg) mice expressing transgenic follicle-stimulating hormone alone or in combination with testosterone. Endocrinology. 2003;144:509–17.
Hermann BP, Sukhwani M, Hansel MC, Orwig KE. Spermatogonial stem cells in higher primates: are there differences from those in rodents? Reproduction. 2010;139:479–93.
Conflict of interest
The authors declare none.
Author information
Authors and Affiliations
Corresponding author
Additional information
Capsule The administration of exogenous FSH promotes the recovery from impaired spermatogenesis induced by low-dose doxorubicin.
Rights and permissions
About this article
Cite this article
Hagiuda, J., Ishikawa, H., Kaneko, S. et al. Follicle-stimulating hormone enhances recovery from low-dose doxorubicin-induced spermatogenic disorders in mice. J Assist Reprod Genet 32, 917–923 (2015). https://doi.org/10.1007/s10815-015-0472-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-015-0472-8